NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: CHUK plays an important role in the NF-κB signalling pathway; indirubin and its derivatives inhibited CML cell proliferation by inhibiting CHUK activation of the NF-κB signalling pathway [44].